PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
May 23, 2008Molecular TherapyOpen Access

Recombinant Adeno-associated Virus Transduction and Integration

View Full Paper
Ask AI
Bookmark
Share

Design

Review

Key result

Recombinant adeno-associated virus utilizes multiple pathways for transgene expression and predominantly exists as an episome, though it has a low frequency of host genome integration.

Authors

BSBrian SchultzJCJeffrey S. Chamberlain

Discussion

Loading...

Member takes

Overview

Low but present rAAV integration risk warrants ongoing genomic monitoring in gene therapy; leaves open precise long-term integration frequency and consequences.

Structured PICO

E
Exposure
Recombinant adeno-associated virus (rAAV) gene therapy vectors

This review summarizes the mechanisms of rAAV transduction, highlighting its predominantly episomal nature and low but present risk of host genome integration.

Cite This Study

Schultz et al. (2008) conducted a review in Genetic disorders (e.g., hemophilia, cystic fibrosis, muscular dystrophies). Recombinant adeno-associated virus (rAAV) was evaluated. Recombinant adeno-associated virus utilizes multiple pathways for transgene expression and predominantly exists as an episome, though it has a low frequency of host genome integration.

synapsesocial.com/papers/6aa1f811a2b903368f347a87https://doi.org/10.1038/mt.2008.103
View Full Paper
Ask AI
Bookmark
Share